Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.

byBenzinga Newsdesk

March 7, 2023

1 minute read

HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.

How A Famous, Polarizing Wall Street Short-Seller Sniffs Out Corporate Frauds: ‘What We Look For Is Behavioral’

By Shanthi Rexaline

May 1, 3:39 AM

Muddy Waters founder Carson Block says his firm does not rely on screening criteria as they return a lot of false negatives or false positives.

SPY

Analyst Ratings

Analyst Ratings for Azenta

By Benzinga Insights

May 10, 4:01 PM

Over the past 3 months, 3 analysts have published their opinion on Azenta (NASDAQ:AZTA) stock. These analysts are…

AZTA

W. P. Carey Raises Quarterly Dividend From $1.061/Share To $1.065/Share

By Michael Horton

December 8, 5:31 PM

W. P. Carey Inc. ((W. P. Carey, NYSE:WPC) reported today that its Board of Directors increased its quarterly cash dividend to $1.065 per share, equivalent to an annualized dividend rate of $4.26 per

WPC

Piper Sandler Maintains Overweight on American Equity Inv, Raises Price Target to $44

By Benzinga Newsdesk

December 8, 10:05 AM

Piper Sandler analyst John Barnidge maintains American Equity Inv (NYSE:AEL) with a Overweight and raises the price target from $40 to $44.

AEL

HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

Related Posts

How A Famous, Polarizing Wall Street Short-Seller Sniffs Out Corporate Frauds: ‘What We Look For Is Behavioral’

Analyst Ratings for Azenta

W. P. Carey Raises Quarterly Dividend From $1.061/Share To $1.065/Share

Piper Sandler Maintains Overweight on American Equity Inv, Raises Price Target to $44